 BOSTON, Aug. 24, 2021 GLOBE NEWSWIRE -- Atea Pharmaceuticals, Inc. Nasdaq: AVIR Atea, a clinical-stage biopharmaceutical company, today announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal, Antimicrobial Agents and Chemotherapy. The article titled, Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses, can be accessed here. The published data demonstrate that AT-752 has potent in vitro activity against multiple dengue virus serotypes and other flaviviruses tested, and reduces viremia and improves survival in an animal model of dengue disease. 